NumFin

China Resources Double-Crane Pharmaceutical Co.,Ltd.

Simbolis: 600062.SS

SHH

23.35

CNY

Rinkos kaina šiandien

  • 17.5971

    P/E santykis

  • -0.5329

    PEG koeficientas

  • 24.20B

    MRK kapitalizacija

  • 0.01%

    DIV pajamingumas

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062-SS) Finansinės ataskaitos

Download
MetinisKetvirtinis
LinijinisLoginis
Diagramoje matote numatytuosius skaičius dinamikoje China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS). Įmonės pajamos rodo NaN M vidurkį, kuris yra NaN % gowth. Vidutinis viso laikotarpio bendrasis pelnas yra NaN M, kuris yra NaN %. Vidutinis bendrojo pelno rodiklis yra NaN %. Įmonės praėjusių metų veiklos grynojo pelno augimas yra NaN %, kuris lygus NaN % % vidutiniškai per visą bendrovės istoriją.,

MetinisKetvirtinis
10Y20Y30Y40Y

Balansas

Pasinerdami į China Resources Double-Crane Pharmaceutical Co.,Ltd. fiskalinę trajektoriją, stebime vidutinį turto augimą. Įdomu tai, kad šis rodiklis yra , atspindintis tiek aukščiausias, tiek žemiausias įmonės rodiklius. Palyginus per ketvirtį, šis skaičius pakoreguojamas iki . Žvilgtelėjus į praėjusius metus, matyti, kad bendras turto pokytis yra NaN. Akcininkų vertė, kurią parodo bendras akcininkų nuosavas kapitalas, vertinama pagal NaN ataskaitine valiuta. Šio aspekto pokytis per metus yra NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994

balance-sheet.row.cash-and-short-term-investments

034572830.73637.6
3262.2
2602.1
1975.7
1248.1
1486.9
778.2
1366.3
1410
1004.7
1104.5
1056.6
1023.5
1028.4
654.3
452
668.7
573.7
444.7
513.7
555.3
302.8
318.7
140.7
337.9
9.2
14.3
1.1

balance-sheet.row.short-term-investments

0240.7200.5803.6
851.9
758.1
878.7
-18
-33.2
-42.6
-31.4
0
0
0
0
0
0
0
0
0.1
0
0
0
0
98.4
0
0
0
0
0
0

balance-sheet.row.net-receivables

02403.52362.82127
2216.7
2130.9
2017.5
1892.7
1864.7
1737.4
1386.6
1886.8
1969.7
1849.3
1408.8
1239.8
1012.2
1358.8
971.1
1095.3
1209.3
1378.7
1197.8
720.6
44.7
37.8
39.6
86.3
23.4
67.9
76.3

balance-sheet.row.inventory

01562.41878.61665.5
1289.3
1146
973.6
974.2
762.8
808.7
653.7
566.1
779.1
701
709.9
600.1
604.5
528.6
466.5
507.3
485.2
563.6
584.7
407.4
174.5
141.5
117.3
30.2
36.5
0
1.8

balance-sheet.row.other-current-assets

0215.592.892.5
32
159.7
168.4
665.1
191.4
435
514.4
18.2
138
42.2
18.2
6.2
37.3
-231
-69.9
-137.1
-129.7
-72.7
-115
0.5
294.9
210.2
79.3
-26.2
-8.3
-3.2
-2.9

balance-sheet.row.total-current-assets

07638.571657522.6
6800.3
6038.7
5135.2
4780.2
4305.8
3759.3
3921.1
3881.2
3891.6
3697
3193.5
2869.6
2682.5
2310.6
1819.6
2134.1
2138.5
2314.2
2181.2
1683.8
816.9
708.3
376.9
428.2
60.8
79
76.3

balance-sheet.row.property-plant-equipment-net

03852.53506.62957.1
2673
2621.8
2632.5
2449.6
2361.4
2444.2
2053.6
2017.5
2027.8
1827.4
1563.2
1432.5
1223.9
997.8
1274.6
1504.9
1552.1
1538.7
1120.4
912.9
452.4
336.9
236
123.7
93.5
53.3
55

balance-sheet.row.goodwill

0906.1935788.2
796.4
839.8
864.4
797
391.7
391.7
109.5
109.5
110.3
66.6
9.1
9.1
9.1
0.8
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

02482.322811899.5
1650.7
1637.4
1525.6
1315.8
1031.9
978
385.4
384.7
343
307.9
233.1
201.7
147.8
163.6
52.2
53.3
74.9
78.5
75.9
45.2
60.3
61.6
67.5
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

03388.332162687.7
2447.1
2477.2
2390
2112.8
1423.6
1369.7
494.9
494.2
453.3
374.5
242.2
210.7
156.9
164.4
52.2
53.3
74.9
78.5
75.9
45.2
60.3
61.6
67.5
0
0
0
0

balance-sheet.row.long-term-investments

0403.1149.8-500.2
-481.9
-723.9
-855.9
20.1
49.7
64.3
53
0
0
0
0
0
0
0
0
109.6
0
0
0
98.7
40.7
0
0
0
0
0
0

balance-sheet.row.tax-assets

0192124.773.8
52.2
50.3
53.5
50.2
42.8
29.2
27.7
29.9
21.7
23.6
27.2
27
24.6
14.3
0
0
0
0
0
5.7
111.5
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

022.1320.6935.1
925.7
812.7
951
24.9
58.3
96.5
68.9
58.1
113.5
154.4
179.4
177.1
181.2
186.3
112.9
11.4
259.7
326.4
239
0
2.4
78
60.6
22.8
0
0
0

balance-sheet.row.total-non-current-assets

078587317.66153.5
5616.2
5238.2
5171
4657.7
3935.8
4003.8
2698.2
2599.7
2616.2
2380
2012.1
1847.4
1586.6
1362.8
1439.7
1679.2
1886.7
1943.6
1435.3
1062.5
667.3
476.6
364.1
146.5
93.5
53.3
55

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

015496.514482.513676.1
12416.5
11276.9
10306.2
9437.9
8241.5
7763.1
6619.3
6480.9
6507.8
6077
5205.5
4717
4269
3673.5
3259.3
3813.3
4025.3
4257.9
3616.5
2746.3
1484.2
1184.8
741
574.7
154.3
132.3
131.3

balance-sheet.row.account-payables

0696.7744.5847.4
848
690.8
547.3
469.2
395.7
400.7
488.4
428.5
959.9
718.3
568.3
518.1
440.5
593
624.2
745.1
924.6
1041.8
829.2
499.7
192.8
116.4
33.1
19.6
8.2
11.5
18

balance-sheet.row.short-term-debt

0432.932.129.5
6.6
64.9
75
0
0
30
0
210
295
400.7
279.4
278
341.5
311
318.5
717.8
885.4
875.8
697.9
374.5
249.3
186.6
106
75
31.5
0.4
0

balance-sheet.row.tax-payables

065.7201.7138.9
122.6
131.3
153.6
113.9
108.7
121.4
68.2
112.3
62.9
150.7
68.7
55.7
60.9
120.3
65.2
101.4
113.6
94.6
131.3
84.9
69.9
41.2
21.3
2.4
-0.2
0
0

balance-sheet.row.long-term-debt-total

029.9232.935.4
151
0.5
7
1.5
1.5
11.2
1.2
0
0
0
13.4
0
0
16
23
4.1
4.1
204
8.6
52
1
2.3
10
0
4
0
0

Deferred Revenue Non Current

0180.6198.8153.8
100.9
97.8
113.8
108.2
111.4
132.7
108.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

01822.32042.357.2
43.9
43.9
1352.2
739.9
619.6
120.4
337.9
89.6
65.9
59.6
52
43.8
29.3
68.8
31.4
55.8
38.1
43.6
49
32.1
18.2
35.7
0.7
0
2.6
3.5
18.4

balance-sheet.row.total-non-current-liabilities

0364741.1468.6
369.5
258.9
269.6
380.2
187.8
224.9
108.6
115.8
118.7
81.8
89.5
54.1
41.3
52.2
29.9
52.4
65.5
264.7
45.9
106.3
6.7
7.2
11
0
4
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

029.932.935.4
121.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

03526.13752.93199.5
3039.5
2600.3
2397.6
1589.3
1203.1
1329.2
934.9
1144.7
1801
1733.7
1279.6
1182.2
1118.6
1308.8
1264.1
1874
2297.9
2541.2
2011.6
1256.3
628.9
473.6
199.6
101.8
48.5
29.2
36.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

01039.71043.21043.2
1043.2
1043.2
1043.2
869.4
724.5
724.5
571.7
571.7
571.7
571.7
571.7
571.7
476.4
441.1
441.1
441.1
441.1
441.1
441.1
339.3
305.7
235.2
147
147
88
86.8
86.8

balance-sheet.row.retained-earnings

09670.68560.98196.4
7580.1
6892.1
6186.8
5517.4
4939.2
4374.9
3643.3
3296.9
2610.9
2216
1867.4
1511.8
1249.4
980.8
527
462.5
326.3
289
244.3
171.4
132.8
71.9
86.5
38
4.5
1.9
1.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

0380594.3561.9
566.8
563.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

00-175.7103.9
103.9
103.9
609.9
1070
1022.5
1007.2
1464.1
1464.1
1471
1470
1424.1
1387.1
1353.7
775.6
847.5
824.3
771
761.7
718.8
772
352.1
385.2
300.5
287.9
13.3
14.4
6.2

balance-sheet.row.total-stockholders-equity

011090.410022.69905.5
9294.1
8602.5
7839.9
7456.8
6686.2
6106.7
5679.1
5332.7
4653.6
4257.7
3863.2
3470.5
3079.5
2197.5
1815.5
1727.9
1538.4
1491.8
1404.2
1282.8
790.6
692.2
534
472.9
105.8
103.1
94.9

balance-sheet.row.total-liabilities-and-stockholders-equity

015496.514482.513676.1
12416.5
11276.9
10306.2
9437.9
8241.5
7763.1
6619.3
6480.9
6507.8
6077
5205.5
4717
4269
3673.5
3259.3
3813.3
4025.3
4257.9
3616.5
2746.3
1484.2
1184.8
741
574.7
154.3
132.3
131.3

balance-sheet.row.minority-interest

0699.4707571.1
82.9
74.1
68.7
391.8
352.3
327.2
5.2
3.5
53.1
85.6
62.8
64.3
70.9
167.2
179.7
211.4
188.9
224.8
200.7
207.2
64.7
19
7.5
0
0
0
0

balance-sheet.row.total-equity

011789.810729.610476.6
9377
8676.6
7908.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0643.8350.3303.4
370.1
34.3
22.8
2.1
16.5
21.7
21.6
26.7
26.7
64.1
85.3
83.4
81.5
82.9
103.4
109.7
252.2
325.6
194.5
98.7
139.1
70.1
53.2
0
0
0
0

balance-sheet.row.total-debt

0462.926564.9
6.6
64.9
82
0
0
41.2
1.2
210
295
400.7
292.8
278
341.5
311
318.5
721.9
889.5
1079.7
706.4
426.5
250.3
188.9
116
75
35.5
0.4
0

balance-sheet.row.net-debt

0-2753.4-2365.3-2769.1
-2403.6
-1779.1
-1015.1
-1248.1
-1486.9
-737
-1365.1
-1200
-709.7
-703.8
-763.8
-745.5
-686.9
-343.3
-133.5
53.3
315.9
635
192.7
-128.8
45.9
-129.9
-24.7
-262.9
26.3
-13.9
-1.1

Pinigų srautų ataskaita

China Resources Double-Crane Pharmaceutical Co.,Ltd. finansiniame kraštovaizdyje per pastarąjį laikotarpį pastebimas pastebimas laisvųjų pinigų srauto pokytis, rodantis NaN pokytį. Bendrovė neseniai išplėtė savo akcinį kapitalą išleisdama NaN, o tai rodo NaN skirtumą, palyginti su praėjusiais metais. Bendrovės investicinė veikla lėmė grynųjų pinigų panaudojimą, kuris ataskaitine valiuta sudarė NaN. Tai NaN pokytis, palyginti su praėjusiais metais. Tuo pačiu laikotarpiu bendrovė užregistravo NaN, NaN ir NaN, kurie yra svarbūs norint suprasti įmonės investavimo ir grąžinimo strategijas. Bendrovės finansinė veikla lėmė grynųjų pinigų panaudojimą NaN, o per metus skirtumas buvo NaN. Be to, bendrovė skyrė NaN dividendams akcininkams išmokėti. Kartu ji ėmėsi kitų finansinių manevrų, vadinamų NaN, kurie taip pat turėjo didelės įtakos jos pinigų srautams šiuo laikotarpiu. Šie komponentai kartu sudaro išsamų įmonės finansinės būklės ir strateginio požiūrio į pinigų srautų valdymą vaizdą.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

013331215.4972.1
1013.5
1066.5
989.5
882.1
739.2
664.8
543.7
873.4
630.5
552.5
533
463.5
396.5
457.6
179.2
190
-25.4
51.6
146.2
162
138.6
75.3
61.1

cash-flows.row.depreciation-and-amortization

0655.5540.6465
371.7
357.4
343.7
335.8
313.7
269.3
235.6
267.7
214.8
176.4
157.9
135.5
126.4
105.7
99.7
118.3
123.6
101.4
89.6
79.2
43.1
62.6
12.7

cash-flows.row.deferred-income-tax

0-18.1-20.7-23.8
-3.1
-3.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0-1705.53623.8
3.1
3.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-412.6-413.5-143.5
-62.4
-31.3
152.6
-35.3
-276.3
-213.7
-65.7
-368.2
-459.9
-244.8
-202.8
-214.2
-244.3
-197
-119.4
-227.4
103.3
-196.3
-145
-166.8
-26.1
-27.4
-93.2

cash-flows.row.account-receivables

0-488.7-266.2-130.7
-216.2
-369.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0315.7-34.3-384.5
-146.8
-185.1
-4.9
-202.9
31.6
33.5
-85.2
-46.2
-78.1
18.8
-111.8
11.4
-104.9
-64.1
-14.1
-55
75.8
64.8
-58.4
-74.5
-33
-27.9
-87.1

cash-flows.row.account-payables

0-221.6-92.2395.5
303.6
526.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-18-20.7-23.8
-3.1
-3.2
157.5
167.5
-307.9
-247.2
19.5
-321.9
-381.8
-263.6
-91.1
-225.6
-139.4
-133
-105.3
-172.4
27.5
-261.1
-86.6
-92.3
7
0.6
-6.1

cash-flows.row.other-non-cash-items

01798.5-16.147.2
37.3
47.3
-16.8
4.5
-5.4
-19.1
4.7
-226.7
10.5
27.4
21.6
-42.7
53.2
-130.8
144.2
59
252.2
192.3
49.9
66.6
17.2
21.1
5.6

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-604.5-525.5-491.7
-348.1
-241.6
-228.7
-154.8
-110
-168.5
-142.4
-217.7
-221.9
-338.8
-370.2
-285.2
-309.2
-136.2
-171.7
-127.1
-196.8
-376
-252
-175.6
-86.8
-69.9
-130.3

cash-flows.row.acquisitions-net

0-127.2-409.236.6
42.7
-112.8
-257.7
-648.2
1.2
-697.1
149.4
194
-111.3
-50.3
0
0
0
171.8
41.6
12.8
0
43.5
2.2
4.8
0.2
0
0

cash-flows.row.purchases-of-investments

0-2340-1350-3199.9
-2421.4
-3064.1
-2019.7
-1290.8
-735
-2607.5
-1280
-2.9
-4.6
-76.5
0
6.8
0
-24.1
-10.8
-15.7
0
-152.7
-55.7
-59.4
-169.3
-30
-26.8

cash-flows.row.sales-maturities-of-investments

023032951.73051.7
2296
2342.7
1678.7
864.9
1003
2723.7
898.6
119
94.9
55.8
0
2.8
1.2
2
45.4
261.6
11.7
4.5
2.1
103.7
5.7
1
0

cash-flows.row.other-investing-activites

060.9-0.233.4
12.9
6.5
4
96.4
4.2
39.2
22
6.4
34.6
5.7
62.4
43.9
138.1
13
7.7
-21.9
32.7
7.8
-1.3
53.2
-2
0
12.9

cash-flows.row.net-cash-used-for-investing-activites

0-707.8666.8-569.8
-418
-1069.3
-823.5
-1132.5
163.3
-710.1
-352.3
98.9
-208.3
-404.2
-307.8
-231.6
-170
26.6
-87.9
109.7
-152.4
-472.9
-304.7
-73.3
-252.2
-98.8
-144.2

cash-flows.row.debt-repayment

0-9.3-6.2-47.7
-64.3
-306.9
-36.6
0
-40
-182.9
-210
-265
-694.8
-595.3
-283.8
-470.8
-350.3
-314.5
-689.3
-895.3
-983.1
-1113.8
-635.7
-576.7
-358.5
-224.9
-173.6

cash-flows.row.common-stock-issued

0-29.7144.70
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0-1-290.90
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-300.5-801.8-302.6
-319.3
-299.2
-91.1
-193.7
-184.7
-3.4
-199.7
-217.2
-250.8
-155
-145.7
-79.9
-111.3
-93.2
-106.4
-43.9
-48.1
-89.1
-68
-56.2
-41.6
0
-8.9

cash-flows.row.other-financing-activites

0-17.8-337-28.3
-2.5
81.2
-675.4
-99.7
0
-397.7
0
371.5
613.4
694.5
275.5
386.4
723.7
304.6
392.3
775.9
858.8
1457.9
826.1
915.9
365.2
370.2
143.2

cash-flows.row.net-cash-used-provided-by-financing-activities

0-358.3-1291.2-378.6
-386.2
-524.9
-803.1
-293.5
-224.7
-583.9
-409.7
-110.7
-332.3
-55.8
-154
-164.3
262.2
-103.1
-403.4
-163.3
-172.4
255
122.4
283.1
-34.9
145.3
-39.3

cash-flows.row.effect-of-forex-changes-on-cash

03.712.31.3
-0.1
0
0
-0.1
0
0.1
0
-0.4
-0.1
0.8
0
0
0
0.1
0.4
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0585.8729.6393.8
555.9
-154.4
-157.5
-238.9
709.9
-592.5
-43.7
534
-144.5
52.3
47.9
-53.9
423.9
159.1
-187.1
86.1
129
-69
-41.6
350.8
-114.3
178.1
-197.2

cash-flows.row.cash-at-end-of-period

03216.32614.71885.1
1491.3
935.4
1089.8
1247.3
1486.2
776.3
1366.3
1410
876
1020.6
968.2
920.3
974.2
550.3
375
562.1
573.7
444.7
513.7
555.3
204.5
318.7
140.7

cash-flows.row.cash-at-beginning-of-period

02630.41885.11491.3
935.4
1089.8
1247.3
1486.2
776.3
1368.8
1410
876
1020.6
968.3
920.3
974.2
550.3
391.2
562.1
476
444.7
513.7
555.3
204.5
318.7
140.7
337.9

cash-flows.row.operating-cash-flow

01650.81341.71340.9
1360.2
1439.8
1469
1187.1
771.2
701.3
718.4
546.2
396
511.5
509.7
342
331.7
235.5
303.7
139.8
453.7
148.9
140.6
141
172.8
131.5
-13.8

cash-flows.row.capital-expenditure

0-604.5-525.5-491.7
-348.1
-241.6
-228.7
-154.8
-110
-168.5
-142.4
-217.7
-221.9
-338.8
-370.2
-285.2
-309.2
-136.2
-171.7
-127.1
-196.8
-376
-252
-175.6
-86.8
-69.9
-130.3

cash-flows.row.free-cash-flow

01046.3816.1849.2
1012.1
1198.1
1240.3
1032.3
661.2
532.9
576
328.6
174.2
172.7
139.5
56.9
22.5
99.3
132.1
12.6
256.9
-227
-111.4
-34.6
86
61.7
-144.1

Pajamų ataskaitos eilutė

China Resources Double-Crane Pharmaceutical Co.,Ltd. pajamos, palyginti su ankstesniu laikotarpiu, pasikeitė NaN%. Pranešama, kad bendrasis 600062.SS pelnas yra NaN. Bendrovės veiklos sąnaudos yra NaN, palyginti su praėjusiais metais, jos pakito NaN%. Nusidėvėjimo ir amortizacijos sąnaudos yra NaN, o tai yra NaN% pokytis nuo praėjusio ataskaitinio laikotarpio. Pranešama, kad veiklos išlaidos yra NaN, kurios rodo NaN% pokytį per metus. Pardavimo ir rinkodaros išlaidos yra NaN, kuris yra NaN% рokytis, palyginti su praėjusiais metais. Naujausiais duomenimis pagrįsta EBITDA yra NaN, o tai reiškia NaN% augimą per metus. Veiklos pajamos yra NaN, kurios rodo NaN% pokytį, palyginti su praėjusiais metais. Grynųjų pajamų pokytis yra NaN%. Praėjusių metų grynosios pajamos buvo NaN.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994

income-statement-row.row.total-revenue

010089.39446.99111.5
8503.9
9381
8225.1
6421.8
5494.8
5138.4
4281
6834.6
6989.3
6383.4
5366.8
5037.9
4951.5
4556.6
4049.1
4597.4
4195.7
4249.2
3686.3
2382.7
1168.3
723.2
350.7
236.3
208.4
168.1
156.7

income-statement-row.row.cost-of-revenue

04948.24231.84030
3145.2
3430.6
3014.4
2733.7
2576.5
2473.1
2206
4470
4661.5
4321.5
3424.9
3327.6
3417.7
3186.3
2902.8
3365.2
3085.9
3096.8
2544.8
1500.4
634
447.5
227.2
160.9
131.1
103.4
107

income-statement-row.row.gross-profit

05141.25215.15081.5
5358.7
5950.3
5210.7
3688.1
2918.3
2665.3
2075
2364.6
2327.9
2061.9
1941.9
1710.4
1533.8
1370.4
1146.3
1232.3
1109.8
1152.4
1141.5
882.2
534.4
275.6
123.4
75.4
77.3
64.7
49.7

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-14.5639.7612.8
682.9
589.3
-5.2
-6.4
69.3
49.5
27.5
33.3
33
62.5
31.4
22.9
18.6
180.9
48.6
-16.2
12.1
20.3
21.1
19.8
11.3
16.5
12.6
4.4
0
0
0.6

income-statement-row.row.operating-expenses

03684.53901.53978.5
4121.8
4645.2
4031.3
2612.3
2060.8
1918.6
1453.1
1561.8
1613.5
1412.5
1335.3
1163.9
1071.9
913.5
920.4
1017.2
996.7
972.3
932.6
684.3
355.9
173.9
54.6
27.6
23.7
16.7
14.1

income-statement-row.row.cost-and-expenses

08632.68133.48008.5
7267
8075.8
7045.7
5346.1
4637.3
4391.8
3659
6031.7
6275
5734
4760.2
4491.5
4489.6
4099.7
3823.1
4382.3
4082.6
4069.1
3477.4
2184.7
989.9
621.4
281.8
188.5
154.8
120.1
14.1

income-statement-row.row.interest-income

052.988.554.4
48.5
20.3
12
10.9
9.7
26.8
24.4
16.8
12.8
12.2
5.8
5.1
0
0
7.7
15
4.8
5.3
9
3.8
3
0
0
0
0
0
0

income-statement-row.row.interest-expense

015.410.611.6
3.7
9.5
8.2
0
2.4
6.5
4.7
22.5
24.2
23.5
12.5
14.5
12.8
11.4
27
49.4
46.8
48.4
37.3
28.2
18.1
12
-3.5
-0.8
3
3.8
3.9

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

097.38.5-15.8
-14.2
-0.7
4.8
-21.8
49.3
60.1
36.5
263.9
48.4
53.6
10.3
15
8.8
117.8
9.5
12.4
-99.2
-104.7
-27
-20
-6
-2.2
14.5
5.1
-3
-3.8
-3.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-14.5639.7612.8
682.9
589.3
-5.2
-6.4
69.3
49.5
27.5
33.3
33
62.5
31.4
22.9
18.6
180.9
48.6
-16.2
12.1
20.3
21.1
19.8
11.3
16.5
12.6
4.4
0
0
0.6

income-statement-row.row.total-operating-expenses

097.38.5-15.8
-14.2
-0.7
4.8
-21.8
49.3
60.1
36.5
263.9
48.4
53.6
10.3
15
8.8
117.8
9.5
12.4
-99.2
-104.7
-27
-20
-6
-2.2
14.5
5.1
-3
-3.8
-3.9

income-statement-row.row.interest-expense

015.410.611.6
3.7
9.5
8.2
0
2.4
6.5
4.7
22.5
24.2
23.5
12.5
14.5
12.8
11.4
27
49.4
46.8
48.4
37.3
28.2
18.1
12
-3.5
-0.8
3
3.8
3.9

income-statement-row.row.depreciation-and-amortization

0655.5582.3491
444.5
427.3
343.7
335.8
313.7
269.3
235.6
267.7
214.8
176.4
157.9
135.5
126.4
105.7
99.7
118.3
123.6
101.4
89.6
79.2
43.1
62.6
12.7
-1
3
3.8
-45.8

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

01456.71406.11136.9
1229.3
1262.5
1189.3
1060.4
843.2
764.3
638.4
1033.9
731.3
655.2
592.7
542.2
452
393.8
222.1
270
29.9
116.7
208.2
189
175.1
93.2
73.5
48.9
50.7
44.2
31.7

income-statement-row.row.income-before-tax

015541414.61121.2
1215
1261.8
1184.1
1053.9
906.8
806.8
658.4
1066.8
762.8
703
616.9
561.4
470.7
574.7
253.1
240.7
28
106.2
205.6
193.4
179.4
104.6
84.7
53.1
50.7
44.2
31.7

income-statement-row.row.income-tax-expense

0240.6199.3149.1
201.5
195.3
194.7
171.8
167.5
141.9
114.7
193.3
132.2
150.5
83.9
98
74.2
117.1
67.5
51.9
53.4
54.7
59.4
31.3
40.8
29.4
23.6
5.5
-3
0.2
0.2

income-statement-row.row.net-income

013331180.1935.7
1005.2
1055.1
968.6
842.6
714.2
661.1
541.9
870.7
614.4
529
520.1
451.5
380.6
437.6
164.9
186.6
4.7
64.6
168.4
157.7
128.9
75.9
60.9
47.5
50.7
44
31.5
Panašios akcijos
Jus taip pat gali dominti:
CHSYF
China Medical System Holdings Limited.
0.9313 USD
PNK
600479.SS
ZhuZhou QianJin Pharmaceutical Co.,Ltd.
10.92 CNY
SHH
WOCKPHARMA.BO
Wockhardt Limited.
532.5 INR
BSE
185750.KS
Chong Kun Dang Pharmaceutical Corp..
100300 KRW
KSC
ERIS.NS
Eris Lifesciences Limited.
848.1 INR
NSE
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd..
22.39 CNY
SHZ
TKPHF
Takeda Pharmaceutical Company Limited.
26.83 USD
PNK
MVP.AX
Medical Developments International Limited.
0.61 AUD
ASX
APLLTD.NS
Alembic Pharmaceuticals Limited.
1001.35 INR
NSE
128940.KS
Hanmi Pharm. Co., Ltd..
321500 KRW
KSC
002390.KS
HANDOK Inc..
13700 KRW
KSC

Dažnai užduodami klausimai

Kas yra China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) bendras turtas?

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) bendras turtas yra 15496483691.000.

Kokios yra įmonės metinės pajamos?

Metinės pajamos yra N/A.

Kokia yra įmonės pelno marža?

Įmonės pelno marža yra 0.554.

Koks yra įmonės laisvųjų pinigų srautas?

Laisvųjų pinigų srautas yra 1.160.

Kokia yra įmonės grynojo pelno marža?

Grynojo pelno marža yra 0.134.

Kokios yra bendros įmonės pajamos?

Bendrosios pajamos yra 0.147.

Kas yra China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) grynasis pelnas (grynosios pajamos)?

Grynasis pelnas (grynosios pajamos) yra 1333029471.000.

Kokia yra bendra įmonės skola?

Bendra skola yra 462877986.000.

Koks yra veiklos sąnaudų skaičius?

Veiklos sąnaudos yra 3684461873.000.

Koks yra įmonės grynųjų pinigų skaičius?

Įmonės grynieji pinigai yra 0.000.